One of the most significant developments this summer was the results of the first double-blind, active placebo-controlled study to test psilocybin for alcohol use disorder (AUD). Psilocybin significantly reduced the number of heavy drinking days across the 32-week follow-up period. With a large sample size for a clinical trial with psilocybin and positive results, psilocybin-assisted therapy could…


Previous articleatai Life Sciences to Host Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
Next articlePsychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alochol Use Disorder; Former MindMed CMO Alleges IP Was Syphoned off to Competitor; ARK Discusses Psychedelics